Skip to main content
. 2021 Mar 11;12:627819. doi: 10.3389/fendo.2021.627819

Figure 4.

Figure 4

Drug response of GEP-NEC organoids. (A, B) Viability (A) or growth-rate corrected viability (B) of cisplatin-treated GEP-NEC organoids. n = 3–4. NEC-01010: passage (P) 6-14; NEC-01013: P10-19; NEC-02002: P6-16. (C, D) Viability (C) or growth-rate corrected viability (D) of everolimus-treated GEP-NEC organoids. n = 3–5. NEC-01010: P6-16; NEC-01013: P10-20; NEC-02002: P6-17. (E) GR at 25 nM everolimus (corresponding to Cmax). n = 3–5. Error bars represent s.e.m. Student’s t test. *P < 0.05; **P < 0.01.